Targeted radiation plus hormone therapy for prostate cancer spread
Part of Cancer, Kidney & urinary clinical trials.
This study compares different ways of giving radiation (SABR or brachytherapy) along with long-term hormone therapy for men whose prostate cancer has spread to a limited number of spots in the body. It aims to see which radiation approach controls the cancer as well as possible while keeping quality of life in mind.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to sign the study consent form
- Your prostate cancer has been confirmed as adenocarcinoma (a specific prostate cancer type)
- Your cancer has spread (M1), but you do not have a high number of spots (fewer than 5 bone metastases and no spread to organs like the lung/liver)
- You have not had prostate cancer treatment before, except hormone therapy (and you plan to stay on it longer than 9 months)
- You are well enough for study activities (performance status 0 to 2) and can complete quality-of-life questionnaires
- If you might be assigned to brachytherapy, your bladder and prostate size must be suitable, and you must not have had certain prostate procedures before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the use of radiation to the prostate and to all visible spots where cancer has spread, in men who have up to 10 small areas of spread when first diagnosed. The goal is to see if this approach can help control the cancer.
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
This trial tests whether giving radiotherapy to the prostate and a few cancer spots elsewhere in the body can help control low-spread prostate cancer. It is for people who have not had any previous prostate cancer treatment.
This trial tests combining hormone therapy with different types of radiation (including high-dose external beam and brachytherapy) for men with prostate cancer that has a higher chance of coming back. It aims to see if adding radiation to the lymph nodes helps control the cancer better.
This study looks at whether combining prostate surgery with a highly focused radiation treatment (SBRT) can control prostate cancer that has spread to a limited number of bones. It may help patients by treating the main tumor and the specific metastatic spots in a controlled way.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
Hear when a new Oligometastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.